Evaluation of systemic chemotherapy with magnetic liposomal doxorubicin and a dipole external electromagnet

International Journal of Cancer

Volumn 109, Issue 4, 2004, Pages 627-635

  Nobuto, Hiroo ^a   Sugita, Takashi ^b   Kubo, Tadahiko ^a   Shimose, Shoji ^a   Yasunaga, Yuji ^a   Murakami, Teruo ^a   Ochi, Mitsuo ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA PREFECTURAL HOSPITAL   (Japan)

Author keywords

Doxorubicin; Drug delivery; External electromagnet; Magnetic liposome; Osteosarcoma

Indexed keywords

DOXORUBICIN; LIPOSOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DIPOLE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TARGETING; ELECTROMAGNETIC RADIATION; HAMSTER; HEART; HISTOPATHOLOGY; KIDNEY; LIVER; LUNG; MAGNETIC FIELD; MAGNETISM; MALE; NONHUMAN; OSTEOSARCOMA; PARTICLE SIZE; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CRICETINAE; DOXORUBICIN; DRUG CARRIERS; ELECTROMAGNETICS; EVALUATION STUDIES; LIPOSOMES; LUNG NEOPLASMS; MAGNETICS; MALE; MESOCRICETUS; NEOPLASMS, EXPERIMENTAL; OSTEOSARCOMA; SURVIVAL RATE;

EID: 1542510110     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20035     Document Type: Article

References (26)

1. Uchida A, Myoui A, Araki N, Yoshikawa H, Shinto Y, Ueda T. Neoadjuvant chemotherapy for pediatric osteosarcoma patients. Cancer 1997;79:411-5.
2. Gabizon A, Meshorer A, Barenholz Y. Comparative long-term study of toxicities of free and liposome-associated doxorubicin in mice after i.v. administration. J Natl Cancer Inst 1986;77:459-69.
3. Lasic DD. Doxorubicin in sterically stabilized liposomes. Nature 1996;380:561-2.
4. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46:6387-92.
5. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, Jain RK. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995;55:3752-6.
6. Gabizon A, Price DC, Huberty J, Bresalier RS, Papahadjopoulos D. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. Cancer Res 1990;50:6371-8.
7. Nitta Y, Sugita T, Ikuta Y, Murakami T. Inhibitory effect of liposomal MDP-Lys on lung metastasis on transplantable osteosarcoma in hamster. Oncol Res 2000;12:25-31.
8. Fidler IJ, Sone S, Fogler WE. Eradication of spontaneous metastases and activation of alveolar macrophages by i.v. injection of liposome containing muramyl dipeptide. Proc Natl Acad Sci USA 1981;78:1680-4.
9. Gupta PK, Hung CT. Comparative disposition of Adriamycin delivered via magnetic albumin microspheres in presence and absence of magnetic field in rats. Life Sci 1990;46:471-9.
10. Widder KJ, Morris RM, Poore G, Howard DPJ, Senyei AE. Tumor remission in Yoshida sarcoma-bearing rats by selective targeting of magnetic albumin microspheres containing doxorubicin. Proc Natl Acad Sci USA 1981;78:579-81.
11. Jain SK, Vyas SP. Magnetically responsive diclofenac sodium-loaded erythrocytes: preparation and in vitro characterization. J Microencapsul 1994; 11: 141-51.
12. Orekhova NM, Akchurin RS, Belyaev AA, Smirnov MD, Ragimov SE, Orekhov AN. Local prevention of thrombosis in animal arteries by means of magnetic targeting of aspirin-loaded red cells. Thromb Res 1990;57:611-6.
13. Ranney DF. Magnetically controlled devices and biomodulation. In: Tyle P, ed. Drug delivery devices. New York: Marcel Dekker, 1988. 325-68.
14. Alexios CA, Arnold W, Klein RJ, Parak FG, Hulin P, Bergmann C, Erhardt W, Wagenpfeil S, Lübbe AS. Locoregional cancer treatment with magnetic drug targeting. Cancer Res 2000;60:6641-8.
15. Kubo T, Sugita T, Shimose S, Nitta Y, Ikuta Y, Murakami T. Targeted delivery of drugs with i.v. administered magnetic liposomes in osteosarcoma-bearing hamsters. Int J Oncol 2000;17:309-15.
16. Kubo T, Sugita T, Shimose S, Nitta Y, Ikuta Y, Murakami T. Targeted systemic chemotherapy using magnetic liposomes with incorporated Adriamycin for osteosarcoma in hamsters. Int J Oncol 2001;18:121-5.
17. Bacon BR, Stark DD, Park CH, Saini S, Groman EV, Hahn PF, Compton CC, Ferrucci JT. Ferrite particles: a new magnetic resonance imaging contrast agent. Lack of acute or chronic hepatotoxicity after i.v. administration. J Lab Clin Med 1987;110:164-71.
18. Babincová M, Čičmanec P, Altanerová V, Altaner C, Babinec P. AC-magnetic field controlled drug release from magnetoliposomes: design of a method for site-specific chemotherapy. Bioelectrochemistry 2002;55:17-9.
19. Gupta PK, Hung CT. Magnetically controlled targeted micro-carrier system. Life Sci 1989;44:175-86.
20. Homma M, Okada M, Minowa T, Kato T, Nemoto R. An approach to magnetically controlled cancer chemotherapy: theoretical basis on magnetic guide of microcapsules in vascular system. J Jap Soc Cancer Ther 1980;15:881-4.
21. Jaffe N, Raynold AK, Ayala A, Carrasco CH, Wallace S, Robertson R, Griffiths M, Wang Y. Effect of cumulative courses of intraarterial cis-diamminedichloroplatin-II on the primary tumor in osteosarcoma. Cancer 1989;63:63-7.
22. Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, Applewhite A, Vlamis V, Rosen G. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992;10:5-15.
23. Jaffe N. Weekly high-dose methotrexate-citrovorum factor in osteogenic sarcoma: pre-surgical treatment of primary tumor and of overt pulmonary metastases. Cancer 1977;39:45-50.
24. Rahman A, More N, Schein PS. Doxorubicin-induced chronic cardiotoxicity and its protection by liposomal administration. Cancer Res 1982;42:1817-25.
25. Herman EH, Rahman A, Ferrans VJ, Vick JA, Schein PS. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res 1983;43:5427-32.
26. Minow RA, Benjamin RS, Gottlieb JA. Adriamycin (NSC-123127) cardiomyopathy: an overview with determination of risk factors. Cancer Chemother Rep Part 3 1975;6:195-201.